Vim & Vigor - Spring 2011 - Parrish Medical Center - (Page 39)

CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TES BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAP LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF MAMMOGRAPHY: There are ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM two types of this breast cancer CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOS screening tool: ﬁlm and digital. RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TES Digital images are stored electronically and can be easily manipulated BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH for a closer look. PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAP TIP: If you are over MAMMOGRAPHY LUMPECTOMY CARCINOGEN the age of 40, be PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS sure to schedule an annual mammogram. PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF Mammograms have been shown to lower the ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGE risk of dying from breast cancer by 35 percent MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC in women over 50. CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG PAP TEST: A screening that gathers cells from MALIGNANT METASTASIS PROGNOSISunder a microscope. the cervix to be examined RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF ANTIGEN TEST BENIGN MALIGNANTand other abnorDEALING WITH DIAGNOSIS This test detects cervical cancer METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH malities such as infection. PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN BENIGN: A tumor that is PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM MALIGNANT METASTASIS not cancerous but can TIP: To prevent discomfort, schedule TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC grow. Your doctor may refer to a benign tumor as CARCINOGEN MAMMOGRAPHY PAPyour Pap test one to two weeks after you expect your period. “nonmalignant.” CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS TIP: Visit cancer.org and click “stay TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP healthy” to PROSTATE-SPECIFIC ANTIGEN TEST: learn how diet, exercise and sun protection can MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF A blood test that measures the level of prostatehelp keep you cancer-free. ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH speciﬁc antigen (PSA), a substance produced PAP TESTprostate. Increased ANTIGEN TEST BENIGN MALIGNANT: A tumor that is cancerous and MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM by the PROSTATE-SPECIFIC levels of PSA may CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGNspread to other can destroy nearby tissues and MALIGNANT METASTASIS PROGNOSIS RECURRENC indicate prostate cancer. CHEMOTHERAPY LUMPECTOMY CARCINOGENvary, but MAMMOGRAPHYof the body. TIP: Recommendations for the PSA test parts PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHYcancer, don’t be TIP: If you are diagnosed with PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIG if you are a man older than 50 (45 for black men), afraid to let loved ones CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIF talk to your doctor about scheduling a PSA test MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY help you. Allow them to help RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPH along with a digital rectal exam. ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSISwith chores, bake dinners or just listen. PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOM 39 Vim & Vigor · SPRI NG 2011 CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENC CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTAS PHOTOGRAPHY BY PHOTOSHOT http://www.cancer.org

Table of Contents for the Digital Edition of Vim & Vigor - Spring 2011 - Parrish Medical Center

Vim & Vigor - Spring 2011 - Parrish Medical Center
Table of Contents
Tasty Tips
Opening Thoughts
Community Calendar
What’s New?
Watch Your Step
A Workout for Every Mood
Don’t Fail Your Heart
If Your Bones Could Talk
Healthy Travels
Over 40 and Fabulous
Do-It-Yourself Health?
Fighting Words
Balancing Act
Giving & Getting
Fitness & Wellness Go Hand in Hand
Stopping PAD in Its Tracks
Community Health
Foundation Focus
Ask the Expert

Vim & Vigor - Spring 2011 - Parrish Medical Center